Abiraterone acetate in the treatment of prostate cancer

Thakur, Abhimanyu; Roy, Aishwarya; Ghosh, Arijit; Chhabra, Mohit; Banerjee, Sugato

doi:10.1016/j.biopha.2018.02.067

Cited by 59 publications

(35 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The mechanisms underlying hypertension caused by abiraterone are well known. The drug is able to inhibit the extra-gonadic production of testosterone by inhibiting the enzyme activity of steroid 17alpha-monooxygenase, which is a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of the steroid intermediates involved in testosterone synthesis, or the direct inhibition of androgen receptor activity [41]. CYP17 is the key enzyme inhibited by abiraterone, which bears components of 17alpha-hydroxylase and 17, 20-lyase and mediates androgen and cortisol synthesis.…”

Section: Renal and Cardiac Toxicitymentioning

confidence: 99%

Renal and Cardiovascular Toxicities by New Systemic Treatments for Prostate Cancer

Saltalamacchia

Frascaroli

Bernardo

et al. 2020

Cancers

View full text Add to dashboard Cite

Prostate cancer (PC) is the most common male cancer in Western Countries. In recent years, the treatment of relapsed or metastatic disease had benefited by the introduction of a variety of new different drugs. In consideration of the relative long survival of PC patients, side effects of these drugs must be considered and monitored. In this review, we analyzed the newly developed therapies for PC treatment, describing the mechanism of action, the metabolism and latest clinical trials that led to the approval of these drugs in clinical practice. We then evaluated the cardiovascular and renal side effects from pivotal phase III and II studies and meta-analyses. Cardiovascular side effects are the most frequent, in particular hypertension, while renal toxicity is rarer and not well described in literature. Therefore, there is a need to better define the effects of these therapies, in order to personalize patient treatment on the basis of their comorbidities and preferences, in addition to their symptoms and disease load.

show abstract

Section: Renal and Cardiac Toxicitymentioning

confidence: 99%

Renal and Cardiovascular Toxicities by New Systemic Treatments for Prostate Cancer

Saltalamacchia

Frascaroli

Bernardo

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…The abiraterone and ADT arm of the STAMPEDE trial also showed improved outcomes [6] . Abiraterone irreversibly inhibits the Cytochrome P450 17α-hydroxylase/17,20-lyase (CYP17) enzyme expressed in adrenal tissues, reducing androgen synthesis from all sources [42] . Although the combination of CYP17 inhibition and ADT demonstrates more effective androgen depletion than either agent alone [43] , resistance to abiraterone develops, likely through increase CYP17 expression [44] , enzymatic alterations [45] , and/or gain of function 3β-hydroxysteroid dehydrogenase type 1 mutation [46] .…”

Section: Clinical Trials Suggest Unique Pca Susceptibilities After Admentioning

confidence: 99%

Combination therapy with androgen deprivation for hormone sensitive prostate cancer: A new frontier

Etheridge

Damodaran

Schultz

et al. 2019

Asian Journal of Urology

View full text Add to dashboard Cite

Androgen deprivation therapy (ADT) has been the standard of care for the last 75 years in metastatic hormone sensitive prostate cancer (PCa). However, this approach is rarely curative. Recent clinical trials have demonstrated that ADT combined with other agents, notably docetaxel and abiraterone, lead to improved survival. The mechanisms surrounding this improved cancer outcomes are incompletely defined. The response of cancer cells to ADT includes apoptosis and cell death, but a significant fraction remains viable. Our laboratory has demonstrated both in vitro and in vivo that cellular senescence occurs in a subset of these cells. Cellular senescence is a phenotype characterized by cell cycle arrest, senescence-associated β-galactosidase (SA-β-gal), and a hypermetabolic state. Positive features of cellular senescence include growth arrest and immune stimulation, although persistence may release cytokines and growth factors that are detrimental. Senescent tumor cells generate a catabolic state with increased glycolysis, protein turnover and other metabolic changes that represent targets for drugs, like metformin, to be applied in a synthetic lethal approach. This review examines the response to ADT and the putative role of cellular senescence as a biomarker and therapeutic target in this context.

show abstract

“…In the context of cancer, C-PC has been shown to induce apoptosis, which led to the enhancement of topotecan effect on prostate cancer cells [ 12 ]. It is noteworthy, prostate cancer claims to be the second most cause for cancer-related mortality in men [ 13 ]. Its photodynamic effect has been shown again breast cancer cells in vitro [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

Phycocyanin Extracted from Oscillatoria minima Shows Antimicrobial, Algicidal, and Antiradical Activities: In silico and In vitro Analysis

Venugopal

Thakur

Chennabasappa

et al. 2020

AIAAMC

Self Cite

View full text Add to dashboard Cite

Background: Phycocyanin is an algae-derived protein, which binds to pigment for harvesting light. It has been reported in various different species, including that of red algae, dinoflagellates, and cryptophyta. Importantly, phycocyanin has enormous applications, including cosmetic colorant, food additive, biotechnology, diagnostics, fluorescence detection probe, an anticancer agent, anti-inflammatory, immune enhancer, etc. In addition, several different algae were utilized for the isolation of cyano-phycocyanin (C-PC), but most of the purification methods consist of several steps of crude extraction. Aim: To isolate C-PC from a new source of microalgae with better purity level and to evaluate its antimicrobial, algicidal, and antiradical activities. Methods: Biological activity, permeability, pharmacokinetics, and toxicity profile of C-PC were predicted by in silico studies. C-PC was purified and isolated by using ammonium sulphate precipitation, ion-exchange chromatography and gel-filtration chromatography. C-PC was characterized by SDS-PAGE and elution profile (purity ratio) analysis. Antimicrobial and algicial activities of C-PC were evaluated by the microtitre plate based assays. Antiradical activity of C-PC was evaluated by DPPH- and ABTS*+ radical scavenging assays. Conclusion: C-PC was extracted from Oscillatoria minima for the first time, followed by its quantitative as well qualitative evaluation, indicating a new alternative source of this important protein. Furthermore, the antimicrobial, algicidal, and antiradical activities of the isolated C-PC extract have been demonstrated by both in silico as well as in vitro methods.

show abstract

Abiraterone acetate in the treatment of prostate cancer

Cited by 59 publications

References 70 publications

Renal and Cardiovascular Toxicities by New Systemic Treatments for Prostate Cancer

Renal and Cardiovascular Toxicities by New Systemic Treatments for Prostate Cancer

Combination therapy with androgen deprivation for hormone sensitive prostate cancer: A new frontier

Phycocyanin Extracted from Oscillatoria minima Shows Antimicrobial, Algicidal, and Antiradical Activities: In silico and In vitro Analysis

Contact Info

Product

Resources

About